Relationship between Calreticulin Gene Mutation and JAK2/MPL Negative Myeloproliferative Neoplasms.
10.7534/j.issn.1009-2137.2015.05.060
- Author:
Lu DONG
1
;
Xu-Liang SHEN
2
;
Wu WEI
3
Author Information
1. The First Clinicial College, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
2. Central Laboratory, Heping Hospital Affilated to Changzhi Medical College, Changzhi 046000, Shanxi Province, China. E-mail: shenxlcyp@sohu.com.
3. Central Laboratory, Heping Hospital Affilated to Changzhi Medical College, Changzhi 046000, Shanxi Province, China.
- Publication Type:Journal Article
- MeSH:
Bone Marrow Neoplasms;
genetics;
Calreticulin;
genetics;
Humans;
Janus Kinase 2;
genetics;
Mutation;
Myeloproliferative Disorders;
genetics;
Receptors, Thrombopoietin;
genetics
- From:
Journal of Experimental Hematology
2015;23(5):1532-1534
- CountryChina
- Language:Chinese
-
Abstract:
In 2008, WHO made the JAK2V617F gene mutation as one of the specific molecular diagnostic markers of BCR/ABL-negative myeloproliferative neoplasms (MPN). In 2013 two research teams demonstrated that whole genome sequencing technology (WGS) was used to detect calreticulin gene mutation in essential thrombocythaemia (ET) and primary myelofibrosis (PMF) patients with JAK2V617F⁻ and MPL⁻ mutations. In this review, the relationship of CALR gene mutation with MPN is briefly summarized.
